AIDS TREATMENT NEWS Issue #250, July 5, 1996 phone 800/TREAT-1-2, or 415/255-0588 CONTENTS: Cryptosporidiosis: NTZ at Buyers' Club; Customs Holds Second Shipment NAC: First Controlled Trial, Positive Results Nevirapine Approved Vancouver Conference: Each Day Summarized Nightly on World Wide Web SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web CMV Retinitis and Treatment: CME Course on World Wide Web Delavirdine Expanded Access Program Information on World Wide Web West Hollywood: AIDS and Chinese Medicine Conference, July 25-28 Neuropathy: Nutrient Therapies World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites ***** Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment NTZ (nitazoxanide), an experimental drug which may be the first effective treatment against cryptosporidiosis (which causes severe diarrhea in persons with AIDS) was recently approved in Mexico, and for the first time is now available at a U.S. AIDS buyers' club, the PWA Health Group in New York. An officially approved compassionate access program recently was expanded from 100 to 150 slots. But for weeks many people who desperately needed this drug found it impossible to obtain, no matter how well connected they were. The PWA Health Group recently called people on its long list to buy NTZ, and found that half of them had died. NTZ is inexpensive to manufacture, and is being studied for treating many parasites in developing countries. In the U.S., it is in phase I trials for cryptosporidiosis. On June 21 a U.S. Customs office seized half of the PWA Health Group shipment of NTZ. Because such cases happen frequently and are usually resolved fairly rapidly, the PWA Health Group suggests that people contact them concerning how they might help if necessary. The shipment may have already been released by the time you receive this newsletter. Meanwhile the PWA Health Group has enough NTZ to treat about 50 people. They require a doctor's prescription for this drug. To obtain a fact sheet on NTZ, to order the drug, or to offer to help politically if necessary, contact the PWA Health Group at 212/255-0520. ***** NAC: First Controlled Trial, Positive Results by John S. James NAC (N-acetylcysteine), a low-cost potential treatment approved for certain non-HIV medical uses, has for years been one of the most popular "alternative" treatments sold by the AIDS buyers' clubs in the U.S. For many years researchers have had well-designed research protocols ready to go to scientifically test whether NAC can be helpful in HIV infection, but finding the funds for this work has been extraordinarily difficult. The first controlled trial started in late 1993 at Stanford University; now its results have been publicly reported at the May 21-24, 1996 meeting OXIDATIVE STRESS AND REDOX REGULATION: CELLULAR SIGNALING, AIDS, CANCER, AND OTHER DISEASES, at the Institut Pasteur in Paris.(1) Although the design of this study was too limited to tell with word 'help' in message body netnews@sift.stanford.edu